Antibiotic treatment of urinary tract infections.
Cefotaxime was compared with ceftezole for clinical efficacy and safety in the treatment of chronic complicated urinary tract infections. Cefotaxime was significantly superior to ceftezole in both overall clinical and bacteriological efficacy. There was no significant intergroup difference in adverse reactions or laboratory parameters. Cefotaxime, therefore, proved to be of considerable value in the treatment of chronic complicated urinary tract infections.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002437:Cefazolin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology
D000900:Anti-Bacterial Agents; C012811:ceftezole; D002437:Cefazolin; D002439:Cefotaxime